| Name | Title | Contact Details |
|---|---|---|
Victoria Romero |
Chief Information Officer | Profile |
We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.
Compassus is a national leader in providing high-quality, compassionate, person-centered care to individuals wherever they call home. Our continuum of integrated home-based care, including home health infusion therapy palliative and hospice care ensures patients and their families have the support they need to address current and future health needs. Partnering with Compassus brings peace of mind to patients, caregivers, and health care providers. Our team members work collaboratively to manage patient conditions and meet goals of care alongside referring physicians, health systems, long-term care partners, and family members. Our value is in the compassion and expertise of our teams, which act as an extension of patients` existing care teams. We believe everyone who interacts with us should experience our individualized `Care for who` I am philosophy, from the care services we provide to patients and families to how we interact with our partners and one another.
Season Health is a food as medicine platform that provides clinical nutrition care, meal recommendations, education, and food delivery to people with chronic conditions such as diabetes and kidney disease.
eStudySite is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.